Alvaro Torres

Publications (7)30.81 Total impact

• Article: Prevalence and changing distribution of HTLV-1 and HTLV-2 infections in Spain

  Ana Treviño, Antonio Aguilera, Estrella Caballero, Rafael Benito, Patricia Parra, Jose M Eiros, Araceli Hernandez, Enrique Calderón, Manuel Rodríguez, Alvaro Torres, Juan García, Jose Manuel Ramos, Lourdes Roc, Goitzane Marcaida, Carmen Rodríguez, Matilde Trigo, Cesar Gomez, Raul Ortíz de Lejarazu, Carmen de Mendoza, Vincent Soriano
  Retrovirology 04/2012; 8:1-2. · 6.47 Impact Factor
• Source

  Available from: PubMed Central

  Article: Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain.

  Ana Treviño, Antonio Aguilera, Estrella Caballero, Rafael Benito, Patricia Parra, Jose M Eiros, Araceli Hernandez, Enrique Calderón, Manuel Rodríguez, Alvaro Torres, Juan García, Jose Manuel Ramos, Lourdes Roc, Goitzane Marcaida, Carmen Rodríguez, Matilde Trigo, Cesar Gomez, Raul Ortíz de Lejarazu, Carmen de Mendoza, Vincent Soriano
  [show abstract] [hide abstract]
  ABSTRACT: Although most HTLV infections in Spain have been found in native intravenous drug users carrying HTLV-2, the large immigration flows from Latin America and Sub-Saharan Africa in recent years may have changed the prevalence and distribution of HTLV-1 and HTLV-2 infections, and hypothetically open the opportunity for introducing HTLV-3 or HTLV-4 in Spain. To assess the current seroprevalence of HTLV infection in Spain a national multicenter, cross-sectional, study was conducted in June 2009. A total of 6,460 consecutive outpatients attending 16 hospitals were examined. Overall, 12% were immigrants, and their main origin was Latin America (4.9%), Africa (3.6%) and other European countries (2.8%). Nine individuals were seroreactive for HTLV antibodies (overall prevalence, 0.14%). Evidence of HTLV-1 infection was confirmed by Western blot in 4 subjects (prevalence 0.06%) while HTLV-2 infection was found in 5 (prevalence 0.08%). Infection with HTLV types 1, 2, 3 and 4 was discarded by Western blot and specific PCR assays in another two specimens initially reactive in the enzyme immunoassay. All but one HTLV-1 cases were Latin-Americans while all persons with HTLV-2 infection were native Spaniards. The overall prevalence of HTLV infections in Spain remains low, with no evidence of HTLV-3 or HTLV-4 infections so far.
  Virology Journal 03/2012; 9:71. · 2.34 Impact Factor
• Article: Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey.

  Ana Treviño, Juan García, Carmen de Mendoza, Rafael Benito, Antonio Aguilera, Raul Ortíz de Lejarazu, José M Ramos, Matilde Trigo, Jose M Eirós, Manuel Rodríguez-Iglesias, Alvaro Torres, Enrique Calderón, Araceli Hernandez, Cesar Gomez, Goizane Marcaida, Vincent Soriano
  [show abstract] [hide abstract]
  ABSTRACT: The presence of antibodies to human T-lymphotropic virus (HTLV) types 1 and 2 was examined in 5742 sera belonging to consecutive adult outpatients attended during June 2008 at 13 different hospitals across Spain. Overall, 58.8% were female. Foreigners represented 8% of the study population. Seven individuals were seropositive for HTLV-2 (overall prevalence 0.12%). No cases of HTLV-1 infection were found. All HTLV-2(+) subjects were Spanish natives, of whom six were coinfected with HIV-1 and five with hepatitis C virus (HCV). Moreover, all but one of the HTLV-2(+) subjects had been intravenous drug users. In summary, this cross-sectional survey suggests that the rate of HTLV infection in Spain is low, and is mostly represented by HTLV-2. Infected individuals are generally Spanish natives with a prior history of intravenous drug use and are coinfected with HIV-1 and/or HCV.
  AIDS research and human retroviruses 08/2010; 26(8):861-4. · 2.18 Impact Factor
• Article: Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR.

  Lourdes S Peña De La Vega, Alvaro Torres, Humberto E Bohorquez, Julie K Heimbach, James M Gloor, Thomas R Schwab, Sandra J Taler, Scott L Nyberg, Michael B Ishitani, Mikel Prieto, Jorge A Velosa, Timothy S Larson, Mark D Stegall, Fernando G Cosio, Stephen C Textor, Matthew D Griffin
  [show abstract] [hide abstract]
  ABSTRACT: Donor age adversely affects deceased-donor kidney transplant outcomes, but its influence on living-donor transplantation is less well characterized. Living-donor kidney transplants at a single center between 1998 and 2000 were reviewed. Data were abstracted for 52 transplants from donors aged > or =50 years and for a matched group of 104 transplants from donors aged <50 years. Survival indices were compared during the first three years' post-transplantation. Functional indices, including serial iothalamate clearances, were compared at 1, 12, and 24 months. Predonation glomerular filtration rate (GFR) was lower among older donors (94 +/- 12 vs. 108 +/- 17 mL/min/SA) but post-transplant compensatory hypertrophy was similar (11.7 +/- 26.3% vs. 7.7 +/- 31.4%). Recipients of older-donor grafts were older (52.8 +/- 16.5 vs. 46.1 +/- 15.1 years) and more frequently unrelated to the donor (54% vs. 39%). Trends toward higher frequency of slow graft function, cytomegalovirus (CMV) infection, and polyomavirus nephropathy were observed for older-donor grafts. Three-year recipient, graft, and death-censored graft survivals were > or =90% for both groups. At 1, 12, and 24 months, serum creatinine was higher and GFR was lower among recipients of older- compared with younger-donor grafts. Other functional indices (urine total protein, serum potassium and uric acid, hemoglobin, and number of antihypertensives) were not different. Donor age correlated with graft GFR at 1, 12, and 24 months for the entire study cohort by linear regression. Older donor age does not preclude excellent results from living-donor kidney transplantation but should be appreciated as being associated with relatively lower GFR.
  Kidney International 10/2004; 66(4):1654-61. · 6.61 Impact Factor
• Article: Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR

  LOURDES S PE|[Ntilde]|A DE LA VEGA, ALVARO TORRES, HUMBERTO E BOHORQUEZ, JULIE K HEIMBACH, JAMES M GLOOR, THOMAS R SCHWAB, SANDRA J TALER, SCOTT L NYBERG, MICHAEL B ISHITANI, MIKEL PRIETO, JORGE A VELOSA, TIMOTHY S LARSON, MARK D STEGALL, FERNANDO G COSIO, STEPHEN C TEXTOR, MATTHEW D GRIFFIN
  [show abstract] [hide abstract]
  ABSTRACT: Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR.Background Donor age adversely affects deceased-donor kidney transplant outcomes, but its influence on living-donor transplantation is less well characterized.
  Kidney International 09/2004; 66(4):1654-1661. · 6.61 Impact Factor
• Article: Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.

  Alvaro Torres, Beatriz Domínguez-Gil, Agustín Carreño, Eduardo Hernández, Enrique Morales, Julian Segura, Ester González, Manuel Praga
  [show abstract] [hide abstract]
  ABSTRACT: Treatment of idiopathic membranous glomerulonephritis (MGN) is a controversial issue. Whereas some authors recommend early immunosuppressive treatment of all patients with nephrotic syndrome, others do not support aggressive therapies, based on the spontaneous long-term favorable outcome of most patients. However, 20 to 50% of untreated patients develop progressive renal insufficiency. All of the patients with biopsy-proven MGN who developed renal insufficiency at our Hospital during the period of 1975 to 2000 were studied. Selected patients (N=39) were separated into two groups according to the two different therapeutic policies followed at our department: a conservative approach during the first period, 1975 to 1989 (group I, N=20), and a course of immunosuppressive therapy (oral prednisone for six months and concurrent oral chlorambucil, 0.15 mg/kg/day, during the first 14 weeks) during the second period, 1990 to 2000 (group II, N=19). There were no significant differences between both groups at the time of renal biopsy, nor at the onset of renal function decline. All group I patients showed a progressive renal insufficiency; at the end of the follow-up 13 patients (65%) were on chronic dialysis, 2 (10%) showed advanced renal failure, and 5 (25%) had died. In contrast, most of group II patients showed an improvement or stabilization of serum creatinine (SCr; 2.3 +/- 0.9 mg/dL at onset of treatment, 2 +/- 1.5 mg/dL at the end of follow-up) together with decreased proteinuria (11.2 +/- 3.3 vs. 5.2 +/- 6.7 g/24 h). At the end of the follow-up 58% of group II patients had a SCr value < or =1.5 mg/dL and 36% showed a complete or partial remission, whereas no patient in group I showed remission. After four years of follow-up the probability of renal survival without dialysis was 55% in group I and 90% in group II (P < 0.001), and after seven years the renal survival was 20% and 90%, respectively (P < 0.001). Side effects of immunosuppressive treatment were uncommon but severe, as two patients suffered Pneumocystis carinii pneumonia. A course of immunosuppressive treatment administered early at the onset of renal function decline induces a favorable effect in most of patients with MGN and deteriorating renal function. Untreated patients progressed without exception toward advanced renal failure.
  Kidney International 01/2002; 61(1):219-27. · 6.61 Impact Factor
• Article: P-239: Metabolic advantages of doxazosin GITS versus hydrochlorothiazide as add-on therapy after antihypertensive monotherapy failure: a prospective trial

  Carlos Campo, Julian Segura, Alvaro Torres, Olga Garcia Vallejo, Luis M Ruilope